Hypoxia promotes the expression of Von Willebrand factor in breast cancer cells by up-regulating the transcription factor YY1 and down-regulating the hsa-miR-424

Tao, Qianying; Lu, Yuxin; Qi, Yanfei; Yu, Die; Gu, Jiayi; Zhu, Yifei; Shi, Chencheng; Liang, Xin

doi:10.1016/j.ejphar.2022.175308

Cited by 9 publications

(4 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, the inception of anti‐angiogenic therapies signifies a pivotal shift in TNBC therapeutic strategies. Bevacizumab, an exemplar of anti‐angiogenic antibodies, has demonstrated substantial clinical efficacy in the neoadjuvant setting of TNBC, marked by enhanced progression‐free survival (PFS) in patients 27,28 . The angiogenic kinase inhibitor, ENMD‐2076, along with lenalidomide, designed to target endothelial cells, have demonstrated potential anti‐TNBC activity.…”

Section: Discussionmentioning

confidence: 99%

“…Bevacizumab, an exemplar of anti-angiogenic antibodies, has demonstrated substantial clinical efficacy in the neoadjuvant setting of TNBC, marked by enhanced progression-free survival (PFS) in patients. 27,28 The angiogenic kinase inhibitor, ENMD-2076, along with lenalidomide, designed to target endothelial cells, have demonstrated potential anti-TNBC activity. Consequently, antiangiogenic therapeutic strategies have emerged as highly promising for the clinical management of TNBC.…”

Section: Single Cellsmentioning

confidence: 99%

See 1 more Smart Citation

Single‐cell combined with bulk‐RNA data reveal a pattern related to angiogenesis in breast cancer patients: Individualized medicine

Zhang,

Yu,

Yang

2023

Environmental Toxicology

View full text Add to dashboard Cite

Angiogenesis contributes to tumor progression, aggressive behavior, and metastasis. Although several endothelial dysfunction genes (angiogenesis‐related genes [ARGs]) have been identified as diagnostic biomarkers of breast cancer in a few studies, the mixed effects of ARGs have not been thoroughly investigated. The RNA sequencing data and patient survival datasets of breast cancer were obtained for further analysis. MSigDB website includes angiogenesis‐related mechanisms. The consensus clustering analysis identifies 1082 breast cancer patients as three clusters. differential expression genes (DEGs) were identified by limma package. GO combined with gene set enrichment analysis (GSEA) to identify cytogenetic functions between two predefined clusters. Then Serpin Family F Member 1 (SERPINF1), angiomotin (AMOT), promyelocytic leukemia (PML), and BTG anti‐proliferation factor 1 (BTG) were selected to construct prediction models using random forest survival analysis. External validation was performed using the GSE58812 triple‐negative breast cancer cohort as the validation set. The median scoring system was used to discern the high‐ and low‐risk groups, and there was a significant difference in their diagnostic results. Immunological infiltration scores were calculated using single sample gene set enrichment analysis (ssGSEA) and xCell algorithms, and consciousness scores were calculated using the R package “oncoPredict” for drugs in the Genomics of Drug Sensitivity in Cancer (GDSC) database. In addition, the single‐cell analysis of seven triple‐negative breast cancers using scRNA‐seq information from GSE118389 demonstrated the interpretation of SERPINF1, AMOT, PML, and BTG1. In conclusion, this investigation engineered ARG‐centric disease paradigms that not only prognosticated prospective therapeutic compounds, but also projected their mechanistic trajectories, thereby facilitating the proposition of tailored treatments within diverse patient cohorts diagnosed with breast cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Single Cellsmentioning

confidence: 99%

Single‐cell combined with bulk‐RNA data reveal a pattern related to angiogenesis in breast cancer patients: Individualized medicine

Zhang,

Yu,

Yang

2023

Environmental Toxicology

View full text Add to dashboard Cite

show abstract

“…Protein extraction and Western blot analysis were conducted as previously described 44 . The cells were lysed using cold RIPA lysate, and centrifuged at 12000rpm for 25 min to remove cell debris.…”

Section: Western Blot Analysismentioning

confidence: 99%

ST2L promotes VEGFA-mediated angiogenesis in gastric cancer by activating TRAF6/PI3K/Akt/NF-κB pathway via IL-33

Zhu,

Lu,

Zhu

et al. 2024

Preprint

Self Cite

View full text Add to dashboard Cite

Tumorigenicity 2 (ST2) is a member of the interleukin-1 receptor/ Toll-like receptor superfamily, and its specific ligand is Interleukin-33 (IL-33). IL-33/ ST2 signaling has been implicated in numerous inflammatory and allergic diseases, as well as in promoting malignant behavior of tumor cells and angiogenesis. However, the precise role of ST2 in gastric cancer angiogenesis remains incompletely elucidated. We observed a significant correlation between high expression of ST2 in gastric cancer tissues and poor prognosis, along with various clinicopathological features. In vitro experiments demonstrated that the IL-33/ ST2 axis activates the PI3K/AKT/NF-κB signaling pathway through TRAF6, thereby promoting VEGFA-mediated tumor angiogenesis; meanwhile sST2 acts as a decoy receptor to regulate the IL-33/ST2L axis. Consistent findings were also observed in subcutaneous xenograft tumor models in nude mice. Furthermore, we investigated the molecular mechanism by which IL-33 promotes ST2L expression in GC cells via upregulation of transcription factors YY1 and GATA2 through intracellular signaling pathways.

show abstract

“…Interestingly, hypoxia-induced Yin and Yang 1 (YY1) transcription factor works as a transcriptional activator of VWF, which in turn promotes angiogenesis and breast cancer cell migration. Although miR-424 works as a negative regulator of VWF expression and post-transcriptionally represses it, hypoxic environment downregulates miR-424 as well to further enhance the expression of VWF and associated angiogenic response ( 90 ). Furthermore, cancer cells tend to release excessive amount of exosomes under hypoxic conditions to communicate with surrounding cells.…”

Section: Hypoxia-driven Ncrnas In Breast Cancermentioning

confidence: 99%

Hypoxia-driven ncRNAs in breast cancer

H. Al-Zuaini,

Rafiq Zahid,

Xiao

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

Low oxygen tension, or hypoxia is the driving force behind tumor aggressiveness, leading to therapy resistance, metastasis, and stemness in solid cancers including breast cancer, which now stands as the leading cause of cancer-related mortality in women. With the great advancements in exploring the regulatory roles of the non-coding genome in recent years, the wide spectrum of hypoxia-responsive genome is not limited to just protein-coding genes but also includes multiple types of non-coding RNAs, such as micro RNAs, long non-coding RNAs, and circular RNAs. Over the years, these hypoxia-responsive non-coding molecules have been greatly implicated in breast cancer. Hypoxia drives the expression of these non-coding RNAs as upstream modulators and downstream effectors of hypoxia inducible factor signaling in the favor of breast cancer through a myriad of molecular mechanisms. These non-coding RNAs then contribute in orchestrating aggressive hypoxic tumor environment and regulate cancer associated cellular processes such as proliferation, evasion of apoptotic death, extracellular matrix remodeling, angiogenesis, migration, invasion, epithelial-to-mesenchymal transition, metastasis, therapy resistance, stemness, and evasion of the immune system in breast cancer. In addition, the interplay between hypoxia-driven non-coding RNAs as well as feedback and feedforward loops between these ncRNAs and HIFs further contribute to breast cancer progression. Although the current clinical implications of hypoxia-driven non-coding RNAs are limited to prognostics and diagnostics in breast cancer, extensive explorations have established some of these hypoxia-driven non-coding RNAs as promising targets to treat aggressive breast cancers, and future scientific endeavors hold great promise in targeting hypoxia-driven ncRNAs at clinics to treat breast cancer and limit global cancer burden.

show abstract

Hypoxia promotes the expression of Von Willebrand factor in breast cancer cells by up-regulating the transcription factor YY1 and down-regulating the hsa-miR-424

Cited by 9 publications

References 39 publications

Single‐cell combined with bulk‐RNA data reveal a pattern related to angiogenesis in breast cancer patients: Individualized medicine

Single‐cell combined with bulk‐RNA data reveal a pattern related to angiogenesis in breast cancer patients: Individualized medicine

ST2L promotes VEGFA-mediated angiogenesis in gastric cancer by activating TRAF6/PI3K/Akt/NF-κB pathway via IL-33

Hypoxia-driven ncRNAs in breast cancer

Contact Info

Product

Resources

About